{
    "clinical_study": {
        "@rank": "58786", 
        "acronym": "POP", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention"
            }, 
            {
                "arm_group_label": "PD0332991", 
                "arm_group_type": "Experimental", 
                "description": "Patients will be randomized 3:1 to be treated with PD0332991 125mg/day orally for a total duration of 14 days (or 100 mg/day for a total duration of 21 days depending on results of interim analysis) with last treatment taken the day previous to the surgical procedure."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase II study trying to identify whether short term treatment with PD0332991\n      yields anti-proliferative response -defined by a low level of Ki67 expression (IHC) at\n      surgery- or induces senescence as determined by SABG expression (IHC) in tumors from\n      patients with early breast cancer non-candidates for neoadjuvant hormonotherapy or\n      chemotherapy, as compared to no treatment."
        }, 
        "brief_title": "Randomized Phase II Study to Assess PD 0332991 in Breast Cancer", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Untreated HR-positive Operable Early Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed written informed consent\n\n          2. Female patients aged 18 years or older.\n\n          3. Histologically or confirmed untreated invasive carcinoma of the breast\n\n          4. No personal history of breast cancer\n\n          5. Candidates for initial breast surgery, with a minimum size of 15 mm measured by\n             breast US. Bilateral and multifocal tumors are allowed, assuming tumor evaluations\n             and pre- and post-treatment biopsies are performed in the same target lesion.\n\n          6. HR-positive (defined as either ER and or PR expression >10% by immunohistochemistry\n             or by PCR) and HER2-negative breast cancer.\n\n          7. High proliferative tumor as defined by either Grade 3 or Ki67 \u226520%\n\n          8. No evidence of metastatic disease.\n\n          9. Eastern Cooperative Oncology Group (ECOG) performance status 0/1.\n\n         10. Left ventricular ejection fraction (LVEF) of at least 50%\n\n         11. Negative pregnancy test in women of childbearing potential within 14 days prior to\n             treatment initiation (premenopausal or less than 12 months of amenorrhea\n             post-menopause, and who have not undergone surgical sterilization).\n\n         12. For women of childbearing potential who are sexually active, agreement to use a\n             highly effective, non-hormonal form of contraception or two effective forms of\n             non-hormonal contraception during and for at least 6 months post-treatment.\n\n         13. Patients must be affiliated to a social security system\n\n        Exclusion Criteria:\n\n          1. Patients non-candidate for upfront breast surgery or candidate for neoadjuvant\n             chemotherapy or hormonotherapy.\n\n          2. Patients with previously treated breast cancer or receiving another concomitant\n             anticancer treatment like chemotherapy, immunotherapy, endocrine treatment, or\n             radiotherapy.\n\n          3. HER2-positive breast cancer\n\n          4. Known hypersensibility to PD0332991 or any of its components.\n\n          5. Difficulty to swallow oral medication\n\n          6. Serious uncontrolled concomitant disease that would put the patient at high risk for\n             treatment-related complications.\n\n          7. Patient whose general clinical condition does not consider postponing surgery\n\n          8. Inadequate organ function, evidenced by the following laboratory results:\n\n               -  Absolute neutrophil count <1,500 cells/mm3\n\n               -  Platelet count <100,000 cells/mm3\n\n               -  Hemoglobin <9 g/dL\n\n               -  Total bilirubin greater than 1,5 times the upper limit of normal (ULN) (unless\n                  the patient has documented Gilbert's syndrome)\n\n               -  Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT])\n                  >2.5 x ULN\n\n               -  Serum creatinine >2.0 mg/dL and/or 177 \u03bcmol/L clearance creatinine <50mL/min\n                  (calculated by Cockcroft-Gault method)\n\n               -  International normalized ratio (INR) and activated partial thromboplastin time\n                  (aPTT) or partial thromboplastin time (PTT) >1.5 x ULN (unless on therapeutic\n                  coagulation)\n\n          9. Uncontrolled hypertension (systolic >150 mmHg and/or diastolic > 100 mmHg) or\n             clinically significant (i.e. active) cardiovascular disease: cerebrovascular\n             accident/stroke or myocardial infarction within 6 months prior to first study\n             medication; unstable angina; CHF of New York Heart Association (NYHA) Grade II or\n             higher; or serious cardiac arrhythmia requiring medication.\n\n         10. Patients with a history of long-QT syndrome or documented family history of long-QT\n             syndrome.\n\n         11. QTc >470\n\n         12. serum potassium level < LLN\n\n         13. Uncontrolled intercurrent illness including but not limited to, known active\n             infection with human immunodeficiency virus (HIV), hepatitis B or C virus or\n             psychiatric illness/social situations that would limit compliance with study\n             requirements.\n\n         14. Assessed by the investigator to be unable or unwilling to comply with the\n             requirements of the protocol.\n\n         15. Pregnant or breastfeeding patients"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "105", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02008734", 
            "org_study_id": "2013-002967-24", 
            "secondary_id": "2013/2016"
        }, 
        "intervention": {
            "arm_group_label": "PD0332991", 
            "intervention_name": "PD0332991", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 6, 2013", 
        "link": {
            "url": "http://www.gustaveroussy.fr/fr/essai/cancers-du-sein-cancer-9"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Villejuif", 
                    "country": "France", 
                    "state": "Val de Marne", 
                    "zip": "94805"
                }, 
                "name": "Gustave Roussy"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Short-term Pre-surgical Study to Assess the Effects of PD 0332991 in HR-positive Early Breast Cancer Patients", 
        "overall_official": {
            "affiliation": "Gustave Roussy, Cancer Campus, Grand Paris", 
            "last_name": "Monica Arnedos, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "percentage of patients who at Day 15 have a natural logarithm of percentage positive IHC staining Ki67 of <1 for each study drug (Ki67 \"absolute\" antiproliferative responders).", 
            "measure": "Anti proliferative response", 
            "safety_issue": "No", 
            "time_frame": "Assessed at Day 15 after randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02008734"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Using NCI CTCAE 4.0", 
                "measure": "Dose Limiting Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Assessed at Day 8 and 15 after randomization"
            }, 
            {
                "description": "Relative change from baseline to surgery in Ki67 IHC expression (\"relative\" antripoliferative responders)", 
                "measure": "Ki67", 
                "safety_issue": "No", 
                "time_frame": "Assessed at Day15 after randomization"
            }
        ], 
        "source": "Gustave Roussy, Cancer Campus, Grand Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gustave Roussy, Cancer Campus, Grand Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}